JP6884860B2 - 操作されたイムノグロブリンラムダ軽鎖座位を有する非ヒト動物 - Google Patents

操作されたイムノグロブリンラムダ軽鎖座位を有する非ヒト動物 Download PDF

Info

Publication number
JP6884860B2
JP6884860B2 JP2019522647A JP2019522647A JP6884860B2 JP 6884860 B2 JP6884860 B2 JP 6884860B2 JP 2019522647 A JP2019522647 A JP 2019522647A JP 2019522647 A JP2019522647 A JP 2019522647A JP 6884860 B2 JP6884860 B2 JP 6884860B2
Authority
JP
Japan
Prior art keywords
human
light chain
mouse
gene segments
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019522647A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020501516A (ja
JP2020501516A5 (enExample
Inventor
チャングァン グオ，
チャングァン グオ，
フェイス ハリス，
フェイス ハリス，
ベラ ボロニナ，
ベラ ボロニナ，
ジョン マクウィルター，
ジョン マクウィルター，
ナターシャ レベンコバ，
ナターシャ レベンコバ，
リン マクドナルド，
リン マクドナルド，
ナシン トゥ，
ナシン トゥ，
アンドリュー ジェイ． マーフィー，
アンドリュー ジェイ． マーフィー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2020501516A publication Critical patent/JP2020501516A/ja
Publication of JP2020501516A5 publication Critical patent/JP2020501516A5/ja
Application granted granted Critical
Publication of JP6884860B2 publication Critical patent/JP6884860B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019522647A 2016-11-04 2017-11-03 操作されたイムノグロブリンラムダ軽鎖座位を有する非ヒト動物 Active JP6884860B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662417845P 2016-11-04 2016-11-04
US62/417,845 2016-11-04
US201762567932P 2017-10-04 2017-10-04
US62/567,932 2017-10-04
PCT/US2017/060006 WO2018128691A1 (en) 2016-11-04 2017-11-03 Non-human animals having an engineered immunoglobulin lambda light chain locus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021036180A Division JP2021090455A (ja) 2016-11-04 2021-03-08 操作されたイムノグロブリンラムダ軽鎖座位を有する非ヒト動物

Publications (3)

Publication Number Publication Date
JP2020501516A JP2020501516A (ja) 2020-01-23
JP2020501516A5 JP2020501516A5 (enExample) 2020-12-10
JP6884860B2 true JP6884860B2 (ja) 2021-06-09

Family

ID=62025924

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2019522647A Active JP6884860B2 (ja) 2016-11-04 2017-11-03 操作されたイムノグロブリンラムダ軽鎖座位を有する非ヒト動物
JP2021036180A Withdrawn JP2021090455A (ja) 2016-11-04 2021-03-08 操作されたイムノグロブリンラムダ軽鎖座位を有する非ヒト動物
JP2022109658A Active JP7386292B2 (ja) 2016-11-04 2022-07-07 操作されたイムノグロブリンラムダ軽鎖座位を有する非ヒト動物
JP2023023312A Withdrawn JP2023053400A (ja) 2016-11-04 2023-02-17 操作されたイムノグロブリンラムダ軽鎖座位を有する非ヒト動物
JP2025135726A Pending JP2025166207A (ja) 2016-11-04 2025-08-18 操作されたイムノグロブリンラムダ軽鎖座位を有する非ヒト動物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2021036180A Withdrawn JP2021090455A (ja) 2016-11-04 2021-03-08 操作されたイムノグロブリンラムダ軽鎖座位を有する非ヒト動物
JP2022109658A Active JP7386292B2 (ja) 2016-11-04 2022-07-07 操作されたイムノグロブリンラムダ軽鎖座位を有する非ヒト動物
JP2023023312A Withdrawn JP2023053400A (ja) 2016-11-04 2023-02-17 操作されたイムノグロブリンラムダ軽鎖座位を有する非ヒト動物
JP2025135726A Pending JP2025166207A (ja) 2016-11-04 2025-08-18 操作されたイムノグロブリンラムダ軽鎖座位を有する非ヒト動物

Country Status (26)

Country Link
US (3) US10820582B2 (enExample)
EP (4) EP4567119A3 (enExample)
JP (5) JP6884860B2 (enExample)
KR (4) KR102492433B1 (enExample)
CN (2) CN114369157A (enExample)
AU (3) AU2017391167B2 (enExample)
BR (1) BR112019008675A2 (enExample)
CA (1) CA3038720A1 (enExample)
CY (2) CY1123491T1 (enExample)
DK (3) DK3766343T3 (enExample)
ES (3) ES2823305T3 (enExample)
FI (1) FI4082334T3 (enExample)
HR (3) HRP20250695T1 (enExample)
HU (3) HUE071595T2 (enExample)
IL (2) IL266282B2 (enExample)
LT (3) LT3407709T (enExample)
MA (2) MA53935A (enExample)
MX (2) MX385857B (enExample)
PL (3) PL3766343T3 (enExample)
PT (3) PT4082334T (enExample)
RS (3) RS63390B1 (enExample)
RU (1) RU2757665C2 (enExample)
SG (2) SG10201913483XA (enExample)
SI (3) SI3766343T1 (enExample)
SM (3) SMT202000558T1 (enExample)
WO (1) WO2018128691A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
CN103025884B (zh) 2010-07-26 2015-11-25 特里安尼公司 转基因动物和使用方法
RU2664185C2 (ru) * 2012-02-01 2018-08-15 Регенерон Фармасьютикалз, Инк. Гуманизированные грызуны, которые экспрессируют тяжелые цепи, содержащие домены vl
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
EP4567119A3 (en) 2016-11-04 2025-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
EP4534560A3 (en) 2018-03-24 2025-06-11 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
IL277355B2 (en) 2018-03-26 2025-01-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
BR112021016173A2 (pt) 2019-02-22 2021-11-03 Regeneron Pharma Roedor geneticamente modificado, métodos de produção de um roedor geneticamente modificado e de produção de um anticorpo anti-nav1.7, célula ou tecido isolado de roedor, linhagem celular imortalizada, embrião de roedor, construto de ácido nucleico de direcionamento, e, hibridoma
KR102953869B1 (ko) * 2019-07-01 2026-04-17 조에티스 서비시즈 엘엘씨 유전자이식 포유동물 및 이의 사용 방법
CN115667532A (zh) * 2020-06-02 2023-01-31 百奥赛图(北京)医药科技股份有限公司 具有共有轻链免疫球蛋白基因座的经遗传修饰的非人动物
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
EP4262373A1 (en) 2020-12-16 2023-10-25 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CA3197426A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
MX2023007401A (es) 2020-12-23 2023-07-06 Regeneron Pharma Acidos nucleicos que codifican anticuerpos modificados por anclaje y usos de los mismos.
JP2024543248A (ja) * 2021-11-10 2024-11-20 トリアニ・インコーポレイテッド トランスジェニック哺乳動物およびその使用方法
GB202217978D0 (en) * 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
US20260123608A1 (en) 2024-08-06 2026-05-07 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07503132A (ja) * 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2645563T3 (es) 2001-11-30 2017-12-05 Amgen Fremont Inc. Animales transgénicos que portan genes de cadena ligera de Ig humana
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
PL2346994T3 (pl) 2008-09-30 2022-04-19 Ablexis, Llc Myszy knock-in do wytwarzania chimerycznych przeciwciał
KR101711222B1 (ko) * 2008-12-18 2017-02-28 에라스무스 유니버시티 메디컬 센터 로테르담 인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
DK3241435T3 (da) * 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
WO2011115476A1 (en) 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
MY195217A (en) 2010-06-22 2023-01-11 Regeneron Pharma MICE Expressing An Immunoglobulin Hybrid Light Chain
CN105861548B (zh) 2011-02-25 2020-01-10 瑞泽恩制药公司 Adam6小鼠
EP4074833A1 (en) 2011-10-17 2022-10-19 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SMT201900296T1 (it) * 2011-12-20 2019-07-11 Regeneron Pharma Topi di catena leggera umanizzata
RS57582B1 (sr) * 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
MX2015010841A (es) 2013-02-20 2016-05-09 Regeneron Pharma Modificacion genetica de ratas.
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
WO2015049517A2 (en) * 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
DK3152312T3 (da) 2014-06-06 2020-04-06 Regeneron Pharma Fremgangsmåder og sammensætninger til modifikation af et mållocus
US9738897B2 (en) 2014-06-23 2017-08-22 Regeneron Pharmaceuticals, Inc. Nuclease-mediated DNA assembly
EP3221457B1 (en) 2014-11-21 2019-03-20 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
MX388784B (es) 2014-12-19 2025-03-20 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida a través de direccionamiento múltiple de una sola etapa.
EP4567119A3 (en) 2016-11-04 2025-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus

Also Published As

Publication number Publication date
MX2021010556A (es) 2021-10-01
CY1123491T1 (el) 2022-03-24
MX385857B (es) 2025-03-18
CN114369157A (zh) 2022-04-19
PT4082334T (pt) 2025-05-21
IL266282A (en) 2019-06-30
ES3035365T3 (en) 2025-09-02
KR20190076024A (ko) 2019-07-01
MA44091A (fr) 2018-10-24
IL266282B2 (en) 2024-04-01
FI4082334T3 (fi) 2025-06-10
JP7386292B2 (ja) 2023-11-24
WO2018128691A8 (en) 2019-02-28
SMT202500204T1 (it) 2025-07-22
EP3766343A1 (en) 2021-01-20
CA3038720A1 (en) 2018-07-12
RU2021129958A (ru) 2021-11-02
SI4082334T1 (sl) 2025-06-30
EP4082334B1 (en) 2025-03-26
SMT202000558T1 (it) 2020-11-10
NZ753456A (en) 2021-08-27
MX2019005256A (es) 2019-08-05
HRP20250695T1 (hr) 2025-08-01
PL3766343T3 (pl) 2022-09-26
SI3407709T1 (sl) 2020-10-30
RS66884B1 (sr) 2025-07-31
EP3407709A1 (en) 2018-12-05
RS63390B1 (sr) 2022-08-31
ES2823305T3 (es) 2021-05-06
AU2017391167A1 (en) 2019-05-30
RU2757665C2 (ru) 2021-10-20
SG10201913483XA (en) 2020-03-30
EP3766343B1 (en) 2022-05-11
SI3766343T1 (sl) 2022-06-30
LT3407709T (lt) 2020-10-12
KR102319069B1 (ko) 2021-11-01
CY1125474T1 (el) 2025-05-09
JP2020501516A (ja) 2020-01-23
JP2021090455A (ja) 2021-06-17
BR112019008675A2 (pt) 2019-07-09
HRP20201403T1 (hr) 2020-11-27
DK3766343T3 (da) 2022-06-20
WO2018128691A1 (en) 2018-07-12
CN109996441A (zh) 2019-07-09
KR20210134059A (ko) 2021-11-08
LT3766343T (lt) 2022-06-10
HUE071595T2 (hu) 2025-09-28
AU2017391167B2 (en) 2024-02-15
HUE061980T2 (hu) 2023-09-28
SG11201903344XA (en) 2019-05-30
DK4082334T3 (da) 2025-06-02
EP3407709B1 (en) 2020-07-29
EP3407709B9 (en) 2021-10-06
AU2024200582B2 (en) 2026-04-09
IL266282B1 (en) 2023-12-01
KR102492433B1 (ko) 2023-01-30
CN109996441B (zh) 2022-02-08
AU2024200582A1 (en) 2024-03-28
JP2022130725A (ja) 2022-09-06
JP2025166207A (ja) 2025-11-05
LT4082334T (lt) 2025-05-26
MA53935A (fr) 2021-12-22
EP4082334A1 (en) 2022-11-02
HUE052087T2 (hu) 2021-04-28
DK3407709T3 (da) 2020-08-31
US20210029978A1 (en) 2021-02-04
PT3407709T (pt) 2020-08-20
US12433264B2 (en) 2025-10-07
RU2019112589A3 (enExample) 2021-03-30
EP4567119A2 (en) 2025-06-11
PT3766343T (pt) 2022-05-30
JP2023053400A (ja) 2023-04-12
SMT202200259T1 (it) 2022-07-21
AU2026205397A1 (en) 2026-07-30
KR20240055863A (ko) 2024-04-29
US20180125043A1 (en) 2018-05-10
EP4567119A3 (en) 2025-09-24
US10820582B2 (en) 2020-11-03
KR20230020550A (ko) 2023-02-10
PL3407709T3 (pl) 2021-01-11
PL4082334T3 (pl) 2025-08-11
HRP20220888T1 (hr) 2022-10-28
RU2019112589A (ru) 2020-12-04
ES2915609T3 (es) 2022-06-23
US20260068860A1 (en) 2026-03-12
IL308197A (en) 2024-01-01
KR102658529B1 (ko) 2024-04-19
RS60886B1 (sr) 2020-11-30

Similar Documents

Publication Publication Date Title
JP7386292B2 (ja) 操作されたイムノグロブリンラムダ軽鎖座位を有する非ヒト動物
JP2026016575A (ja) 操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用
JP2024019660A (ja) 免疫グロブリン重鎖コーディング配列におけるｄｈ－ｄｈ再構成が可能な非ヒト動物
HK40082722A (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
HK40082722B (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
HK40127071A (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
HK40045047B (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
HK40045047A (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
HK40001433B (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
HK40001433A (en) Non-human animals having an engineered immunoglobulin lambda light chain locus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201030

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20201030

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20201119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210308

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210421

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210512

R150 Certificate of patent or registration of utility model

Ref document number: 6884860

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250